You are here

Article Text

Article menu
Download PDFPDF
Miscellanea
Journal club
Delaminid for multidrug-resistant pulmonary tuberculosis
  1. Richard J Lessells
  1. Correspondence to Dr Richard J Lessells, Department of Clinical Research, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK; richard.lessells@lshtm.ac.uk

https://doi.org/10.1136/thoraxjnl-2012-202520

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Delaminid (OPC-67683) is an investigational drug for tuberculosis from a new class (nitro-dihydro-imidazooxazole derivatives) that inhibits synthesis of mycolic acid. This multicentre phase 2 randomised clinical trial evaluated the efficacy and safety of delaminid at two doses (100 mg bd, 200 mg bd) versus placebo administered for 8 weeks in combination with a standardised background regimen for multidrug-resistant pulmonary …

    View Full Text

    Footnotes

      • ▸ Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delaminid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151–60.

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.